Lilly Eli & Co insider trades: Sigilon Therapeutics (SGTX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Lilly Eli & Co reports to the SEC
and 7 more companies
Open-market buys and sales
23 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 11, 2023 | SGTX | ↑ Buy | 1,718,493 | $14.92 | $25.6M | Direct | Aug 14, 2023 (3d) |
| Nov 30, 2022 | AKUS | ↑ Buy | 29,992,668 | $12.50 | $374.9M | Direct | Dec 1, 2022 (1d) |
| Jan 22, 2021 | PRVL | ↑ Buy | 34,284,789 | $22.50 | $771.4M | Direct | Jan 22, 2021 (0d) |
| Dec 8, 2020 | SGTX | ↑ Buy | 300,000 | $18.00 | $5.4M | Direct | Dec 10, 2020 (2d) |
| Feb 20, 2020 | DERM | ↑ Buy | 40,926,025 | $18.75 | $767.4M | Direct | Feb 20, 2020 (0d) |
| Jan 31, 2019 | ZYME | ↓ Sell | 250,000 | $16.00 | $4.0M | Direct | Feb 4, 2019 (4d) |
| Nov 6, 2018 | ZYME | ↓ Sell | 700,000 | $14.00 | $9.8M | Direct | Nov 8, 2018 (2d) |
| Sep 24, 2018 | ZYME | ↓ Sell | 2,027 | $16.36 | $33K | Direct | Sep 26, 2018 (2d) |
| Sep 18, 2018 | ZYME | ↓ Sell | 6,870 | $14.56 | $100K | Direct | Sep 20, 2018 (2d) |
| Sep 17, 2018 | ZYME | ↓ Sell | 15,874 | $14.58 | $231K | Direct | Sep 18, 2018 (1d) |
| Sep 13, 2018 | ZYME | ↓ Sell | 30,959 | $14.49 | $448K | Direct | Sep 14, 2018 (1d) |
| Sep 11, 2018 | ZYME | ↓ Sell | 15,777 | $14.75 | $233K | Direct | Sep 12, 2018 (1d) |
| Aug 31, 2018 | ZYME | ↓ Sell | 700 | $14.26 | $10K | Direct | Sep 4, 2018 (4d) |
| Aug 30, 2018 | ZYME | ↓ Sell | 5,752 | $14.31 | $82K | Direct | Aug 31, 2018 (1d) |
| Aug 14, 2018 | ZYME | ↓ Sell | 3,000 | $14.28 | $43K | Direct | Aug 16, 2018 (2d) |
| Aug 13, 2018 | ZYME | ↓ Sell | 6,429 | $14.32 | $92K | Direct | Aug 14, 2018 (1d) |
| Aug 3, 2018 | ZYME | ↓ Sell | 1,650 | $13.55 | $22K | Direct | Aug 7, 2018 (4d) |
| Aug 2, 2018 | ZYME | ↓ Sell | 19,400 | $13.31 | $258K | Direct | Aug 3, 2018 (1d) |
| Apr 12, 2016 | AGLE | ↑ Buy | 500,000 | $10.00 | $5.0M | by fund | Apr 14, 2016 (2d) |
| Nov 12, 2014 | CHRS | ↑ Buy | 164,963 | $13.50 | $2.2M | Direct | Nov 12, 2014 (0d) |
| Apr 15, 2014 | CERU | ↑ Buy | 733,445 | $7.00 | $5.1M | Indirect | Apr 15, 2014 (0d) |
| Jul 6, 2011 | UTHR | ↓ Sell | 49,103 | $54.99 | $2.7M | Direct | Jul 6, 2011 (0d) |
| Jun 29, 2011 | UTHR | ↓ Sell | 189,734 | $54.05 | $10.3M | Direct | Jul 1, 2011 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Lilly Eli & Co's insider trades
Lilly Eli & Co is a 10% owner of Sigilon Therapeutics (SGTX). Since Jun 29, 2011, it has reported 8 open-market purchases worth $1.96B and 15 sales worth $28.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (5 filings), other transactions (3 filings), shares returned to the company (1 filing), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SGTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.